Arctic Bioscience AS (OSL:ABS)

Market Cap	80.87M -7.6%
Revenue (ttm)	42.62M -4.0%
Net Income	-41.03M
EPS	-1.52
Shares Out	26.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,900
Open	3.140
Previous Close	3.240
Day's Range	2.960 - 3.140
52-Week Range	2.600 - 4.650
Beta	1.09
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Arctic Bioscience AS

Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis; and the HeROPA study, an international phase IIb clinical trial. It also sells nutraceuticals as an intermediary and finished goods products under the ROMEGA brand name. Arctic Bioscienc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 19
• Stock Exchange: Oslo Børs
• Ticker Symbol: ABS

Financial Performance

In 2025, Arctic Bioscience AS's revenue was 42.62 million, a decrease of -4.00% compared to the previous year's 44.39 million. Losses were -41.03 million, -14.41% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 15, 2026

Data Sources Report a data error